 | |
| Names | |
|---|---|
| Preferred IUPAC name (5Z)-7-{(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]heptan-5-yl}hept-5-enoic acid | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.164.944 |
| EC Number |
|
| |
| |
| Properties | |
| C21H34O4 | |
| Molar mass | 350.49 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
U46619 is a stable syntheticanalog of the endoperoxideprostaglandin PGH2 first prepared in 1975,[1] and acts as athromboxane A2 (TP) receptor agonist. It potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations and exhibits many properties similar tothromboxane A2, including shape change and aggregation ofplatelets[2] and smooth muscle contraction. U46619 is avasoconstrictor that mimics the hydroosmotic effect ofvasopressin.[3]
 | Thismolecular biology article is astub. You can help Wikipedia byadding missing information. |
